Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.

Morrow, Riley J; Allam, Amr H; Yeo, Belinda; Deb, Siddhartha; Murone, Carmel; Lim, Elgene; Johnstone, Cameron N; Ernst, Matthias

Morrow, Riley J; Allam, Amr H; Yeo, Belinda; Deb, Siddhartha; Murone, Carmel; Lim, Elgene; Johnstone, Cameron N; Ernst, Matthias.

Afiliación

Morrow RJ; Olivia Newton-John Cancer Research Institute, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Allam AH; La Trobe University School of Cancer Medicine, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Yeo B; Olivia Newton-John Cancer Research Institute, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Deb S; La Trobe University School of Cancer Medicine, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Murone C; Olivia Newton-John Cancer Research Institute, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Lim E; Department of Anatomical Pathology, Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Johnstone CN; Olivia Newton-John Cancer Research Institute, 145 Studley Rd, Heidelberg, VIC 3084, Australia.
Ernst M; Department of Anatomical Pathology, Austin Hospital, 145 Studley Rd, Heidelberg, VIC 3084, Australia.

Cancers (Basel) ; 14(9)2022 May 04.

Article en En | MEDLINE | ID: mdl-35565421

Palabras clave

HER2; Tocilizumab; heterogeneity; inflammatory breast cancer; interleukin-6; pSTAT3; paracrine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google